Caladrius Biosciences Stock News

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news. Avenue Therapeutics,

Gainers Akerna Corp. (NASDAQ: KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday. SciSparc Ltd. (NASDAQ: SPRC) gained 68% to $1.3101 after the company announced it entered into an agreeme

All Merger-related proposals approved at the Annual Meeting of Stockholders All Merger-related proposals approved at the Annual Meeting of Stockholders

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 58.3% to $0.1935 in pre-market trading. NewAge shares tumbled around 47% on Thursday on continued weakness after the company recently announced it file

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations

Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics

BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the

BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d

Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de

Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor Relations & Corporate Communications David Mazzo -

Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements